Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis
Objective This study evaluated the benefits of immune checkpoint inhibitors (ICIs) and/or targeted therapies in mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) patients with advanced or recurrent endometrial cancer (EC) via network meta-analysis.Methods English databases were...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20565623.2025.2541517 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849329579498405888 |
|---|---|
| author | Yi Tang Yan Chen Ting Zeng Kui Huang Jing Zhao Pu Zhang Chuqiang Shu |
| author_facet | Yi Tang Yan Chen Ting Zeng Kui Huang Jing Zhao Pu Zhang Chuqiang Shu |
| author_sort | Yi Tang |
| collection | DOAJ |
| description | Objective This study evaluated the benefits of immune checkpoint inhibitors (ICIs) and/or targeted therapies in mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) patients with advanced or recurrent endometrial cancer (EC) via network meta-analysis.Methods English databases were searched from inception through January 2025. Randomized controlled trials (RCTs) assessing the efficacy and safety of related therapies for patients with EC stratified by MMR status were included. The main evaluation indicators included progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), and severe adverse events (SAEs).Results Ten studies were included in the analysis. The results indicated that in the dMMR population, ICIs provide superior survival benefits. Among these, Dostarlimab combined with carboplatin and paclitaxel (CP) had the highest PFS and OS rates. For the pMMR population, Selinexor + CP offers significant benefits over CP alone, although OS outcome data are limited. In pMMR patients with prior chemotherapy, the lenvatinib + pembrolizumab strategy may provide additional PFS benefits relative to chemotherapy treatment.Conclusions ICIs offered advantages for the dMMR population, whereas selinexor could provide survival benefits for the pMMR population. For pMMR patients who have received prior chemotherapy, the lenvatinib plus pembrolizumab strategy shows promise. |
| format | Article |
| id | doaj-art-e4792f070cab42f3a497cdced64cd3b8 |
| institution | Kabale University |
| issn | 2056-5623 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Future Science OA |
| spelling | doaj-art-e4792f070cab42f3a497cdced64cd3b82025-08-20T03:47:13ZengTaylor & Francis GroupFuture Science OA2056-56232025-12-0111110.1080/20565623.2025.2541517Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysisYi Tang0Yan Chen1Ting Zeng2Kui Huang3Jing Zhao4Pu Zhang5Chuqiang Shu6Department of Obstetrics and Gynecology, Maternal and Child Health Hospital of Hunan Province, Changsha, ChinaDepartment of Obstetrics and Gynecology, Maternal and Child Health Hospital of Hunan Province, Changsha, ChinaThe Ministry of Education and Science, Maternal and Child Health Hospital of Hunan Province, Changsha, ChinaDepartment of Obstetrics and Gynecology, Maternal and Child Health Hospital of Hunan Province, Changsha, ChinaDepartment of Obstetrics and Gynecology, Maternal and Child Health Hospital of Hunan Province, Changsha, ChinaDepartment of Obstetrics and Gynecology, Maternal and Child Health Hospital of Hunan Province, Changsha, ChinaDepartment of Obstetrics and Gynecology, Maternal and Child Health Hospital of Hunan Province, Changsha, ChinaObjective This study evaluated the benefits of immune checkpoint inhibitors (ICIs) and/or targeted therapies in mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) patients with advanced or recurrent endometrial cancer (EC) via network meta-analysis.Methods English databases were searched from inception through January 2025. Randomized controlled trials (RCTs) assessing the efficacy and safety of related therapies for patients with EC stratified by MMR status were included. The main evaluation indicators included progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), and severe adverse events (SAEs).Results Ten studies were included in the analysis. The results indicated that in the dMMR population, ICIs provide superior survival benefits. Among these, Dostarlimab combined with carboplatin and paclitaxel (CP) had the highest PFS and OS rates. For the pMMR population, Selinexor + CP offers significant benefits over CP alone, although OS outcome data are limited. In pMMR patients with prior chemotherapy, the lenvatinib + pembrolizumab strategy may provide additional PFS benefits relative to chemotherapy treatment.Conclusions ICIs offered advantages for the dMMR population, whereas selinexor could provide survival benefits for the pMMR population. For pMMR patients who have received prior chemotherapy, the lenvatinib plus pembrolizumab strategy shows promise.https://www.tandfonline.com/doi/10.1080/20565623.2025.2541517Endometrial cancermismatch repairsurvivalimmune checkpoint inhibitorstargeted therapiesmeta-analysis |
| spellingShingle | Yi Tang Yan Chen Ting Zeng Kui Huang Jing Zhao Pu Zhang Chuqiang Shu Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis Future Science OA Endometrial cancer mismatch repair survival immune checkpoint inhibitors targeted therapies meta-analysis |
| title | Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis |
| title_full | Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis |
| title_fullStr | Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis |
| title_full_unstemmed | Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis |
| title_short | Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis |
| title_sort | immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer a meta analysis |
| topic | Endometrial cancer mismatch repair survival immune checkpoint inhibitors targeted therapies meta-analysis |
| url | https://www.tandfonline.com/doi/10.1080/20565623.2025.2541517 |
| work_keys_str_mv | AT yitang immunecheckpointinhibitorsortargetedtherapybymismatchrepairstatusinendometrialcancerametaanalysis AT yanchen immunecheckpointinhibitorsortargetedtherapybymismatchrepairstatusinendometrialcancerametaanalysis AT tingzeng immunecheckpointinhibitorsortargetedtherapybymismatchrepairstatusinendometrialcancerametaanalysis AT kuihuang immunecheckpointinhibitorsortargetedtherapybymismatchrepairstatusinendometrialcancerametaanalysis AT jingzhao immunecheckpointinhibitorsortargetedtherapybymismatchrepairstatusinendometrialcancerametaanalysis AT puzhang immunecheckpointinhibitorsortargetedtherapybymismatchrepairstatusinendometrialcancerametaanalysis AT chuqiangshu immunecheckpointinhibitorsortargetedtherapybymismatchrepairstatusinendometrialcancerametaanalysis |